CEL-SCI Past Earnings Performance

Past criteria checks 0/6

CEL-SCI's earnings have been declining at an average annual rate of -2.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 72.6% per year.

Key information

-2.2%

Earnings growth rate

6.1%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-72.6%
Return on equity-343.5%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How CEL-SCI makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:LSRM Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-2990
31 Mar 240-3090
31 Dec 230-3190
30 Sep 230-3290
30 Jun 230-3490
31 Mar 230-3590
31 Dec 220-37100
30 Sep 220-38110
30 Jun 220-37110
31 Mar 220-36120
31 Dec 210-37130
30 Sep 210-37130
30 Jun 210-34130
31 Mar 210-35130
31 Dec 201-33120
30 Sep 201-30120
30 Jun 201-30110
31 Mar 201-32100
31 Dec 190-2990
30 Sep 190-2280
30 Jun 191-3260
31 Mar 191-2660
31 Dec 181-2450
30 Sep 180-3260
30 Jun 180-2270
31 Mar 180-2070
31 Dec 170-2470
30 Sep 170-1460
30 Jun 170-1080
31 Mar 170-1080
31 Dec 160-1070
30 Sep 160-1280
30 Jun 160-2070
31 Mar 160-2180
31 Dec 151-25100
30 Sep 151-35140
30 Jun 151-32150
31 Mar 150-30150
31 Dec 140-31140
30 Sep 140-28110
30 Jun 140-2380
31 Mar 140-257-5
31 Dec 130-1270

Quality Earnings: LSRM is currently unprofitable.

Growing Profit Margin: LSRM is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: LSRM is unprofitable, and losses have increased over the past 5 years at a rate of 2.2% per year.

Accelerating Growth: Unable to compare LSRM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LSRM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: LSRM has a negative Return on Equity (-343.45%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 11:38
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CEL-SCI Corporation is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew FeinChardan Capital Markets, LLC
Christian OrqueraFirst Berlin Equity Research GmbH
Vernon BernardinoH.C. Wainwright & Co.